Cited 0 times in
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.